Persistent Asset Partners LTD Sage Therapeutics, Inc. Transaction History
Persistent Asset Partners LTD
- $119 Billion
- Q1 2025
A detailed history of Persistent Asset Partners LTD transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Persistent Asset Partners LTD holds 42,216 shares of SAGE stock, worth $385,432. This represents 0.28% of its overall portfolio holdings.
Number of Shares
42,216
Previous 53,721
21.42%
Holding current value
$385,432
Previous $389 Million
13.83%
% of portfolio
0.28%
Previous 0.32%
Shares
2 transactions
Others Institutions Holding SAGE
# of Institutions
218Shares Held
50MCall Options Held
220KPut Options Held
312K-
Black Rock Inc. New York, NY5.22MShares$47.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$46.4 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY4.48MShares$40.9 Million4.6% of portfolio
-
Tig Advisors, LLC New York, NY2.73MShares$24.9 Million1.36% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.09MShares$19.1 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $543M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...